Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective

BACKGROUND AND OBJECTIVES: Major depressive disorder (MDD) is a common and severe psychiatric disorder that has enormous economical and societal costs. As pharmacogenetics is one of the key tools of precision psychiatry, we analyze the cost–utility of test screening of CYP2C19 and CYP2D6 for patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Carta, Andrea, Del Zompo, Maria, Meloni, Anna, Mola, Francesco, Paribello, Pasquale, Pinna, Federica, Pinna, Marco, Pisanu, Claudia, Manchia, Mirko, Squassina, Alessio, Carpiniello, Bernardo, Conversano, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427916/
https://www.ncbi.nlm.nih.gov/pubmed/35930170
http://dx.doi.org/10.1007/s40261-022-01182-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9427916/
https://www.ncbi.nlm.nih.gov/pubmed/35930170
http://dx.doi.org/10.1007/s40261-022-01182-2

Ejemplares similares